Axitinib: In advanced, treatment-experienced renal cell carcinoma

Drugs

Volumn 72, Issue 18, 2012, Pages 2375-2384

  Yang, Lily P H ^a   McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Axitinib; Renal cancer

Indexed keywords

AXITINIB; PAZOPANIB; SORAFENIB; SUNITINIB;

ADVANCED CANCER; ARTICLE; ASTHENIA; BLOOD PRESSURE; CANCER INCIDENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETROPERITONEAL HEMORRHAGE; SEPSIS; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84871245545     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209230-000000000-00000     Document Type: Article

References (33)

1. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011 Oct; 60 (4); 615-21
2. Cho E, Adami HO, Lindblad P. Epidemiology of renal cell cancer. Hematol Oncol Clin North Am 2011 Aug; 25 (4); 651-65
3. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma; the 2010 update. Eur Urol 2010 Sep; 58 (3); 398-406
4. Abdollahi A, Folkman J. Evading tumor evasion; current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010 Feb-Apr; 13 (1-2); 16-28
5. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010 Aug; 36 (5); 416-24
6. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 Feb 10; 23 (5); 1011-27
7. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004 Feb; 93 (3); 297-302
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology; kidney cancer (version 2.2012). online. Available from URL; :http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf. Accessed 2012 Nov 8.
9. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011; 11 (2); 113-26
10. Pfizer Inc. Inlyta® (axitinib) oral tablets; US prescribing information. online. Available from URL; :http://labeling.pfizer.com/ ShowLabeling.aspx?id=759. Accessed 2012 Nov 8.
11. European Medicines Agency. Inlyta® film-coated tablets; summary of product characteristics. online. Available from URL; :http://www.emea.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002406/WC500132188. pdf. Accessed 2012 Nov 8.
12. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008 Nov 15; 14 (22); 7272-83
13. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, and oral angiogenesis inhibitor, in patients with advanced solid tumors; results from a phase I study. J Clin Oncol 2005 Aug 20; 23 (24); 5464-73
14. Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma; management of treatment-related toxicities. Invest New Drugs. Epub 2010 Feb 12
15. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer; a phase II study. Lancet Oncol 2007; 8 (11); 975-84
16. Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy; a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 2011; 47 (17); 2592-602
17. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (27); 4462-8
18. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS); a randomised phase 3 trial. published erratum appears in Lancet 2012 Nov 24; 380 (9856); 1818.
19. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS); a randomised phase 3 trial Lancet 2011 Dec 3; 378 (9807); 1931-9
20. Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11); 3841-9
21. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 2009 May; 20 (5); 966-7
22. Rini BI, Grünwald V, Fishman MN, et al. Axitinib for first-line metastatic renal cell carcinoma (mRCC); overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. abstract no. 4503. J Clin Oncol 2012; 30 Suppl.
23. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs; implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20 (1-2); 79-86
24. Pithavala YK, Chen Y, Toh M, et al. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemother Pharmacol 2012 Jul; 70 (1); 103-12
25. Tortorici MA, Toh M, Rahavendran SV, et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs 2011 Dec; 29 (6); 1370-80
26. Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010 Feb; 65 (3); 563-70
27. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors; pharmacokinetic and clinical results. J Clin Oncol 2005 Aug 20; 23 (24); 5474-83
28. Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC); a Cochrane systematic review of published randomised trials. BJU Int 2011 Nov; 108 (10); 1556-63
29. Michaelson MD, Rini BI, Escudier BJ, et al. Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma; updated results among cytokine-treated patients. abstract no. 4546. J Clin Oncol 2012; 30 Suppl.
30. McKee A. FDA Oncologic Drugs Advisory Committee review. online. Available from URL; :http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM283656.pdf. Accessed 2012 Nov 8.
31. Trask PC, Bushmakin AG, Cappelleri JC, et al. Health-related quality of life during treatment for renal cell carcinoma; results from a phase II study of axitinib. Acta Oncol 2008; 47 (5); 843-51
32. Inlyta® tablets. Japanese prescribing information. Tokyo; Pfizer, 2012. Inlyta® tablets Japanese prescribing information. Tokyo: Pfizer, 2012
33. Pfizer. Axitinib (AG-013736) for the treatment of metastatic renal cell cancer. ClinicalTrials.gov identifier NCT00920816. US National Institutes of Health, ClinicalTrials.gov. online. Available from URL; :http://clinicaltrials. gov. Accessed 2012 Nov 8.